Search research articles
Contact Us
Filters
Showing results (1-10 of 14) with videos related to
Page
of 2
Sort By:
Multiple Sclerosis and Related Disorders
|
April 17, 2015
CCSVI-A. A call to clinicans and scientists to vocalise in an Internet age
Arie R Gafson, Gavin Giovannoni
BMJ Case Reports
|
July 14, 2012
Observations and hypothesis on an individual patient topically treated for capecitabine-induced Palmar-Plantar syndrome
Arie R Gafson, Olivia Goodkin, Richard Begent
Plos One
|
January 13, 2017
Inflammatory Activity on Natalizumab Predicts Short-Term but Not Long-Term Disability in Multiple Sclerosis
Joel Raffel, Arie R Gafson, Samer Dahdaleh, et al.
Frontiers in Neurology
|
July 31, 2018
Remote Monitoring in the Home Validates Clinical Gait Measures for Multiple Sclerosis
Akara Supratak, Gourab Datta, Arie R Gafson, et al.
Frontiers in Cellular Neuroscience
|
August 20, 2024
New views on the complex interplay between degeneration and autoimmunity in multiple sclerosis
Peter K Stys, Shigeki Tsutsui, Arie R Gafson, et al.
Neurology(R) Neuroimmunology & Neuroinflammation
|
October 5, 2018
Mononuclear cell transcriptome changes associated with dimethyl fumarate in MS
Arie R Gafson, Kicheol Kim, Maria T Cencioni, et al.
Multiple Sclerosis and Related Disorders
|
July 17, 2023
Assessing the utility of magnetic resonance imaging-based "SuStaIn" disease subtyping for precision medicine in relapsing-remitting and secondary progressive multiple sclerosis
Xiaotong Jiang, Changyu Shen, Bastien Caba, et al.
Neurology(R) Neuroimmunology & Neuroinflammation
|
May 16, 2019
Breaking the cycle: Reversal of flux in the tricarboxylic acid cycle by dimethyl fumarate
Arie R Gafson, Constantinos Savva, Tom Thorne, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
April 6, 2021
A randomized study of natalizumab dosing regimens for relapsing-remitting multiple sclerosis
Maria Trojano, Lluís Ramió-Torrentà, Luigi Me Grimaldi, et al.
CNS Drugs
|
July 29, 2021
Safety, Patient-Reported Well-Being, and Physician-Reported Assessment of Walking Ability in Patients with Multiple Sclerosis for Prolonged-Release Fampridine Treatment in Routine Clinical Practice: Results of the LIBERATE Study
Giovanni Castelnovo, Oliver Gerlach, Mark S Freedman, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 14) with videos related to
Sort By:
Page
of 2
Multiple Sclerosis and Related Disorders
|
April 17, 2015
CCSVI-A. A call to clinicans and scientists to vocalise in an Internet age
Arie R Gafson, Gavin Giovannoni
BMJ Case Reports
|
July 14, 2012
Observations and hypothesis on an individual patient topically treated for capecitabine-induced Palmar-Plantar syndrome
Arie R Gafson, Olivia Goodkin, Richard Begent
Plos One
|
January 13, 2017
Inflammatory Activity on Natalizumab Predicts Short-Term but Not Long-Term Disability in Multiple Sclerosis
Joel Raffel, Arie R Gafson, Samer Dahdaleh, et al.
Frontiers in Neurology
|
July 31, 2018
Remote Monitoring in the Home Validates Clinical Gait Measures for Multiple Sclerosis
Akara Supratak, Gourab Datta, Arie R Gafson, et al.
Frontiers in Cellular Neuroscience
|
August 20, 2024
New views on the complex interplay between degeneration and autoimmunity in multiple sclerosis
Peter K Stys, Shigeki Tsutsui, Arie R Gafson, et al.
Neurology(R) Neuroimmunology & Neuroinflammation
|
October 5, 2018
Mononuclear cell transcriptome changes associated with dimethyl fumarate in MS
Arie R Gafson, Kicheol Kim, Maria T Cencioni, et al.
Multiple Sclerosis and Related Disorders
|
July 17, 2023
Assessing the utility of magnetic resonance imaging-based "SuStaIn" disease subtyping for precision medicine in relapsing-remitting and secondary progressive multiple sclerosis
Xiaotong Jiang, Changyu Shen, Bastien Caba, et al.
Neurology(R) Neuroimmunology & Neuroinflammation
|
May 16, 2019
Breaking the cycle: Reversal of flux in the tricarboxylic acid cycle by dimethyl fumarate
Arie R Gafson, Constantinos Savva, Tom Thorne, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
April 6, 2021
A randomized study of natalizumab dosing regimens for relapsing-remitting multiple sclerosis
Maria Trojano, Lluís Ramió-Torrentà, Luigi Me Grimaldi, et al.
CNS Drugs
|
July 29, 2021
Safety, Patient-Reported Well-Being, and Physician-Reported Assessment of Walking Ability in Patients with Multiple Sclerosis for Prolonged-Release Fampridine Treatment in Routine Clinical Practice: Results of the LIBERATE Study
Giovanni Castelnovo, Oliver Gerlach, Mark S Freedman, et al.
Page
of 2